The tariff war didn’t just reshape trade policy — it handed Chinese studios the keys to the most lucrative summer box office on the planet.
The numbers tell the story with unusual bluntness. By the time the 2025 calendar year closed, China’s domestic box office had posted ¥51.8 billion yuan ($7.4 billion USD) — up nearly 22% over 2024 and the second-highest total in five years. Of the 51 films grossing more than ¥100 million, 33 were domestic titles. Entering 2026, the momentum has only accelerated: by late May, China’s year-to-date box office (including pre-sales) had already surpassed ¥150 billion yuan ($2.1 billion USD), with the top five films all domestic productions — racing comedy Pegasus 3, action thriller Scare Out, animated franchise Boonie Bears: The Hidden Protector, and the surprise breakout Dear You. That’s not an anomaly. It’s a policy outcome dressed up as a market result.
The collapse of the U.S.-China trade framework, which accelerated through late 2025 and hardened into a formal tariff regime affecting theatrical imports by Q1 2026, has effectively reduced Hollywood’s Chinese release window from a competitive disadvantage into a near-impossibility. Under the existing import framework, American studios face a remittance rate of just 25% on Chinese grosses — already far below what they earn in other markets — and the quota of 34 revenue-sharing titles per year has itself been put under pressure. In April 2025, China’s National Film Administration made the terms explicit: the U.S. government’s “abuse of tariffs” would “inevitably further reduce the domestic audience’s favorability towards American films,” and Beijing would “moderately reduce” the number of American films imported. For a tentpole carrying $250 million in production costs, the math no longer works.
Chinese studios, who have watched Hollywood drain market oxygen for twenty years, are not mourning the situation. They planned for it.
The Infrastructure Moment
China’s major production houses — Wanda Pictures, Bona Film Group, Beijing Culture, and the increasingly muscular streaming-backed arms of iQIYI and Youku — spent the 2023–2025 cycle quietly stockpiling IP, upgrading visual effects pipelines, and attracting international talent. The results are now visible on screen.
The clearest proof of concept arrived in early 2025, when the animated fantasy Ne Zha 2 grossed ¥15.44 billion yuan ($2.13 billion USD) domestically, drawing 324 million admissions — making it the highest-grossing film in a single market in cinema history, the highest-grossing animated film of all time, and the fifth-highest-grossing film in global box office history. Its success was not an isolated event: 2025’s top domestic titles also included Detective Chinatown 1900 ($496 million), war drama Dead to Rights ($421 million), and animated hit Nobody ($245 million). Local films took 79.67% of total box office for the year, roughly one percentage point higher than 2024.
The 2026 Spring Festival period extended this pattern. Pegasus 3 led the holiday charts; spy thriller Scare Out, directed by Zhang Yimou, claimed second with ¥701 million; martial-arts action film Blades of the Guardians followed with ¥577 million. During the nine-day holiday window, China briefly surpassed North America to become the world’s top-grossing film market, with cumulative box office of approximately ¥7 billion yuan ($970 million) against North America’s $938 million. The late-season surprise Dear You — a low-budget Teochew-dialect drama with no major stars — had already grossed ¥896 million ($126 million) by late May on word-of-mouth alone, scoring 85.6 out of 100 in audience satisfaction surveys, the highest rating for any film in the May Day holiday period since tracking began.
The IMAX screen count inside China — now standing at 797 locations, the largest IMAX footprint of any single market globally, representing nearly 44% of IMAX’s entire commercial multiplex network — is being allocated almost entirely to domestic product during the key seasonal windows. During the 2026 Lunar New Year holiday, IMAX delivered $28 million in box office across seven days, with Pegasus 3 alone grossing $24 million — the strongest IMAX performance ever recorded for a Chinese-language film. This scheduling shift would have been commercially inconceivable in 2019, when Avengers: Endgame claimed those premium slots by sheer gravitational pull.
Hollywood’s Shrinking Options
The studios haven’t abandoned China entirely, but their posture has shifted from pursuit to patience. Universal, Warner Bros., and Disney have each publicly maintained that “dialogue remains open” with China Film Group and the National Film Administration — language that translates, in practice, to a holding pattern.
Hollywood accounted for just 5% of China’s overall box office receipts in 2025 — a figure that captures how far the market has already drifted before the latest round of restrictions. Imported superhero franchises experienced notable declines even in a year when the overall market grew. One senior distribution executive at a major American studio, speaking without attribution, described the situation with uncharacteristic candor: “We’re not releasing into China this summer. We’re not refusing to — the economics are refusing for us.”
The structural problem is compounding. Chinese audiences, who spent years being trained to anticipate Hollywood event films as premium cultural experiences, have been re-educated by necessity. A generation of younger moviegoers in Tier 1 and Tier 2 cities is now forming its blockbuster habits around domestic product. Brand loyalty, once Hollywood’s most durable asset in the Chinese market, is being quietly transferred.
The early 2026 box office data points to a complicating wrinkle: year-to-date revenue through late May 2026 was down roughly 43% compared to the same period in 2025 — a gap almost entirely explained by the absence of a Ne Zha 2-scale phenomenon. The market remains structurally top-heavy, and the absence of that kind of breakout hit, domestic or imported, leaves the annual comparison exposed. The summer slate will determine whether 2026 closes as a consolidation year or a contraction.
The Co-Production Variable
The one lane that remains partially open is co-production — and even here, the dynamics have shifted. China’s co-production regulations nominally require at least one-third Chinese creative elements, locations, and cast, but enforcement interpretation has grown stricter in the current climate.
What has emerged instead is a China-adjacent co-production ecosystem that routes through South Korea, Japan, and increasingly through Singapore’s growing production infrastructure. The Korea–China corridor is of particular note. A policy thaw observed throughout late 2025 and early 2026 — marked by a series of Korea–China summits and bilateral cultural cooperation agreements — has begun to reopen formal channels that had been frozen since the 2016 THAAD dispute. CJ ENM, Korea’s leading entertainment company and the force behind the Parasite production pipeline, has moved quickly: alongside Tencent and JYP Entertainment, it launched ONECEAD, a joint venture targeting Chinese-speaking markets, as a direct beneficiary of the thaw. CJ ENM has simultaneously committed to maintaining its annual content investment of $750 million (KRW 1 trillion), positioning Korean production capital as the most credible bridge between Chinese creative ambitions and international audience expectations.
This architecture serves Chinese studios strategically: it brings in technical expertise and limited international marketing leverage without ceding creative or financial control to Hollywood. The Hallyu infrastructure that took two decades to build is now functioning as a geopolitical workaround.
Revenue Projections and the Long View
The 2025 full year delivered ¥51.8 billion yuan in total box office — up 22% on 2024 — but the headline figure obscures a structural concern: sans Ne Zha 2, the rest of the market was actually down from 2024’s comparable baseline. Mid-tier titles, those earning between ¥100 million and ¥500 million, saw a marked decline in number. The market is becoming increasingly bifurcated between phenomenon-scale hits and everything else.
IMAX’s China results provide a more granular indicator of premium-tier health. The company’s 2025 China box office reached $407 million — a record, up 5% over the previous high set in 2019 — with China’s IMAX market share hitting 5.5%, also its highest on record. IMAX has guided to $1.4 billion in global box office for 2026, up from the record $1.28 billion posted in 2025, and its China network remains the single most important geography in that projection.
What the revenue projections cannot fully capture is the qualitative shift underway. Chinese studios are no longer measuring success against what Hollywood would have done with the same slot. They’re measuring against their own expanding baselines — and finding, for the first time with real consistency, that the gap is closeable.
The talent migration dimension is quietly significant. American VFX supervisors, production designers, and second-unit directors have been working on Chinese productions with increasing frequency, drawn by competitive rates and a production environment that, for certain categories of technical crew, now offers comparable or superior infrastructure to mid-major American studio projects. The expertise transfer runs in one direction.
The Bigger Picture
Summer 2026 is not the end of Hollywood’s China story, but it is almost certainly the end of the chapter in which American studios could treat Chinese box office as a predictable top-line boost to their global calculations. The market hasn’t closed — it has restructured around a set of priorities that place Chinese studios at the center by design rather than by default.
For Chinese studios and their government partners, this is the realization of an industrial policy that dates to the post-WTO accession debates of the early 2000s: a domestic film industry capable of filling its own screens, on its own terms, during the highest-grossing period of the theatrical calendar.
Hollywood spent twenty years assuming it would always have a seat at that table. It is now watching from the parking lot, doing math on Southeast Asia, and hoping the tariff climate shifts before its Chinese audience finishes forgetting what it came to see.
The summer, by every available measure, belongs to someone else.
Enjoyed This Story? Subscribe to EntertainLens for more entertainment insights.
